drugset / Trial / NCT00817362
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if IPI-504 in combination with trastuzamab is an effective treatment in HER2 positive metastatic breast cancer
Timeline
- Start
- 2009-03
- Primary completion
- 2010-08
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | retaspimycin | Small molecule | 300 mg/m2 | Intravenous |